53 results about "First pass effect" patented technology

The invention relates to the technical field of traditional Chinese medicine plasters, in particular to a traditional Chinese medicine ointment for preventing relapse of infantile asthma and a preparation method thereof.The traditional Chinese medicine ointment is characterized by sequentially comprising a protective backing layer, a medicine storage layer, a controlled release film layer and an application bonding layer from top to bottom; the traditional Chinese medicine plaster provided by the invention overcomes the defect that the traditional oral traditional Chinese medicine is easily influenced by a first-pass effect and individual differences through an external transdermal administration mode, can continuously maintain efficient medicine concentration at an application part and realize long-acting slow release, and the synergistic effect of the nano micro-emulsion medicine carrying system and the controlled release film layer can realize the sustained release effect of the traditional Chinese medicine. According to the traditional Chinese medicine plaster disclosed by the invention, the stable release of effective components of the medicine is ensured, the penetration rate of the medicine on a skin barrier is also remarkably improved, so that the treatment depth and the action durability of the plaster are enhanced, and meanwhile, the traditional Chinese medicine plaster aims at the pathological mechanism of infantile asthma, relieves airway inflammation, reduces airway hyperresponsiveness and mucus secretion, and has a remarkable curative effect on infantile asthma. The acute attack frequency of asthma can be obviously reduced, and the remission period is prolonged.

The invention relates to the technical field of physiological monitoring, in particular to a hepatocellular carcinoma treatment effect analysis system and method based on metabolism comprehensive analysis, and the method comprises the steps: obtaining the evolution condition of hepatocellular carcinoma, the composition condition of drugs and the composition condition of metabolites; drug absorption and transformation analysis is carried out based on the composition condition of the drug and the marking condition of the composition condition of the metabolite, future drug transformation component prediction is carried out based on the drug absorption and transformation analysis result and the evolution condition of the corresponding hepatocellular carcinoma, and drug treatment effect early warning is carried out based on the future drug transformation component prediction. The first-pass effect is corrected through mass spectrum imaging and enzyme activity, the inhibition effect of the tumor microenvironment on drug transformation is quantified, prediction is dynamically adjusted through the future tumor anomaly score ratio, and the accuracy of the time of drug replacement is improved.

The application discloses a folic acid composition, a folic acid patch and a preparation method thereof. The folic acid composition comprises folic acid, pressure-sensitive adhesive, a fatty compound and an alcohol compound; the fatty compound comprises a fatty acid and / or a fatty acid ester. The folic acid patch comprising the folic acid composition improves the bioavailability of folic acid, reduces the administration frequency, avoids the liver first-pass effect, has good folic acid penetration stability, and the folic acid content in the folic acid patch is basically unchanged after long-time placement.

The invention discloses a dexketoprofen trometamol nasal spray and a preparation method thereof, a buffering agent is used as a stabilizer, and the dexketoprofen trometamol nasal spray which is good in stability, small in irritation, convenient, rapid in effect taking and extremely small in side effect is provided, so that the medication compliance of patients and the convenience of clinical medication are improved; after being administrated, the nasal spray can be quickly absorbed through nasal mucosa, the absorption speed is equivalent to that of intramuscular injection, the nasal spray can quickly reach the peak concentration as intramuscular injection, and the curative effect can be quickly exerted; the preparation has the advantages of no first-pass effect during nasal mucosa administration, high bioavailability and rapid absorption, is suitable for self-rapid analgesia, and is stable in process and suitable for large-scale production.

The invention belongs to the technical field of transdermal patches, and relates to a transdermal patch for improving the bioavailability of estradiol and a preparation method of the transdermal patch. The transdermal patch is prepared from the following components in percentage by weight: 5 to 21 percent of estradiol, 8 to 15 percent of polymer matrix, 0.5 to 1.5 percent of butylated hydroxytoluene, 10 to 15 percent of hydrogenated rosin glyceride, 2 to 5 percent of penetration enhancer, 3 to 8 percent of plasticizer and 25 to 35 percent of solvent. According to the transdermal patch disclosed by the invention, continuous and stable release of a medicine is realized, the transdermal absorption rate of estradiol is improved, so that the bioavailability is improved, the treatment effect is further improved, and meanwhile, the transdermal patch disclosed by the invention can also avoid a first-pass effect of the liver and reduce side effects; the transdermal drug delivery system is convenient to use, and the compliance of a patient is improved.

The invention discloses an oral patch platform based on multi-mechanism synergy and micro-matrix controlled release and a preparation method thereof. The patch comprises core nutrients (such as iron, calcium, folic acid and zinc) and a synergistic nutrient system (such as vitamin C, vitamin D, vitamin B12 and copper), and the release kinetics of different nutrients are accurately regulated and controlled through a physically separated multi-cavity structure (such as a double-semicircular laminated sheet) or a unique hydrophilic-hydrophobic micro-matrix component design; the effects of synergistically promoting absorption, assisting metabolism or preventing antagonism are achieved. According to the invention, the first-pass effect of the liver is avoided through oral mucosa absorption, and the composition can be attached to multiple sites in the oral cavity, so that the absorption efficiency, the bioavailability and the supplement safety of target nutrients are remarkably improved, and the composition is suitable for developing a series of nutritional supplement products or medicine products.

The invention belongs to the technical field of chemical pharmacy, and particularly relates to ursolic acid nanoparticles and a preparation method and application thereof. The nano-particles containing ursolic acid are prepared by taking methoxy polyethylene glycol terminal modified poly (lactic-co-glycolic acid) as a carrier material and ursolic acid as a drug, and the nano-particles can be directly administered by bypassing a blood-brain barrier to treat neurodegenerative diseases; the problems that the liver first-pass effect of the medicine is caused by intravenous injection and oral administration and the intracerebral delivery efficiency is reduced due to medicine interception after the medicine passes through a circulatory system are avoided, and the nano-particles can effectively protect the entrapped medicine from being degraded by hydrolase.

The present invention relates to a percutaneous absorption preparation for relieving pain and, more specifically, to a percutaneous absorption preparation having enhanced drug absorption efficacy. Every ingredient in the percutaneous absorption preparation according to the present invention is uniformly dispersed and does not aggregate, and thus a sufficient anti-inflammatory and pain-relieving efficacy of the drug can be continuously exhibited over a long period of time. In addition, the drug is percutaneously delivered in an amount sufficient for exhibiting efficacy while minimizing skin irritation, which is a disadvantage of percutaneous absorption preparations, and thus a high level of pain-relieving efficacy is exhibited. Moreover, skin penetration promotion in which a consistent amount of percutaneous drug absorption is sustained over a long period of time can be achieved, and thus side effects such as the hepatic first-pass effect in the body can be prevented.

The invention discloses a soluble microneedle based on a CCR6 antagonist, a preparation method of the soluble microneedle and application of the soluble microneedle in treatment of triple negative breast cancer, and belongs to the technical field of biological medicine. Comprising the following steps: mixing a matrix material with an initiator LAP, heating to dissolve, and oscillating; adding a CCR6 antagonist, uniformly mixing, and discharging bubbles in the solution to obtain a mixed solution; and pouring the mixed solution into a microneedle mold, drying, and demolding to obtain the microneedle. The soluble microneedle has the beneficial effects that the soluble microneedle provided by the invention can accurately deliver a CCR6 antagonist to a tumor site, so that the concentration of a drug in tumor tissues is improved, the treatment effect is enhanced, meanwhile, the distribution of the drug in non-target tissues is reduced, the adverse reaction is reduced, and the effect is better through a skin administration mode. The problems of the first pass effect of oral administration and poor drug targeting of intravenous injection administration are avoided, the accuracy of the CCR6 antagonist is improved, and the curative effect of the drug is enhanced.

The invention relates to a suppository for treating postpartum infection and metritis and a preparation method thereof. The suppository for treating postpartum infection and metritis comprises the following raw materials: active pharmaceutical ingredients and auxiliary materials, the mass ratio of the components is 1: (1-2.5). The active pharmaceutical ingredients comprise scutellaria baicalensis, safflower carthamus, angelica sinensis, radix angelicae, poria cocos, liquorice, codonopsis pilosula, radix bupleuri, radix sophorae flavescentis, rhizoma atractylodis and agastache rugosus; the auxiliary materials comprise a matrix and an additive. The suppository has the advantages of being capable of avoiding the first-pass effect of the liver, high in bioavailability, fast in effect taking, convenient to use and the like.

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to sublingual lozenges of progesterone and analogues thereof as well as a preparation method and application of the sublingual lozenges. Specifically, a novel sublingual administration dosage form which is more suitable for being absorbed by a human body is designed according to physicochemical properties of progesterone and analogues thereof. The sublingual lozenge is composed of a main drug, a filler, a disintegrating agent, a mucous membrane promoter, a flavoring agent, a lubricant and the like. The sublingual lozenge is quickly disintegrated under the action of saliva, is quickly absorbed through tongue mucosa, takes effect quickly, avoids the first-pass effect, improves the bioavailability, and is suitable for various clinical scenes needing quick and efficient progestational hormone support.

The invention relates to the technical field of biological medicines, in particular to a hydroxyl-alpha-sanshool gel plaster, a preparation method thereof and application of the hydroxyl-alpha-sanshool gel plaster in preparation of a medicine for treating peripheral neuropathic pain. The preparation method specifically comprises the following steps: (1) mixing hydroxyl-alpha-sanshool with hydroxypropyl-beta-cyclodextrin for reaction, and removing a solvent to obtain a reactant; (2) filtering a reactant, and freeze-drying the reactant to obtain a hydroxyl-alpha-sanshool cyclodextrin inclusion compound; and (3) preparing the hydroxyl-alpha-sanshool cyclodextrin inclusion compound into the hydroxyl-alpha-sanshool gel plaster. The invention aims to construct a hydroxypropyl-beta-cyclodextrin inclusion compound system through a molecular inclusion technology so as to improve the water solubility of HAS and increase the stability of HAS. The prepared gel plaster is used for local treatment of peripheral nerve pathological pain, and aims to avoid loss caused by a first-pass effect, improve patient discomfort caused by frequent administration and reduce side effects caused by systemic administration.

The present invention relates to a formulation of toothpaste for the treatment of various disorders or diseases in the human body by incorporating or adding appropriate active ingredients in therapeutic amount or pharmaceutically effective amount for a particular disorder or disease intended to be treated. In particular, the present invention relates to a toothpaste formulation comprising of one or more active ingredients, oral mucosal absorption enhancers, gelling agents, preservatives, and one or more inactive agents. The present invention provides a novel toothpaste formulation and the process of preparing the same. Oral cavity offers relatively consistent and friendly physiological conditions for drug delivery or drug absorption. Thus, absorption through oral buccal mucosa in the toothpaste under invention by-passes the undesirable first-pass effects in the liver ensuring rapid and better bioavailability and greater efficacy.

The invention discloses a traditional Chinese medicine compound beewax thermal therapy transdermal drug product as well as preparation and application thereof, and belongs to the technical field of external treatment of traditional Chinese medicines. The product is composed of 70%-90% of natural beeswax and 10%-30% of a traditional Chinese medicine compound, and the traditional Chinese medicine compound is selected from medicines for promoting blood circulation to remove blood stasis, dispelling wind and eliminating dampness and the like according to indications; the preparation method comprises the steps of traditional Chinese medicine pretreatment, beewax melting, medicine mixing and forming. During application, treatment is completed through medicinal wax heating, skin pretreatment, medicinal wax application, treatment maintenance and subsequent treatment. The physical effect of beeswax thermal therapy and the pharmacological effect of traditional Chinese medicine are synergistically combined, the continuous thermal effect of beeswax can promote blood circulation, improve the transdermal efficiency of the medicine and enhance the activity of the medicine, and the curative effect is remarkable; the natural beewax is good in biocompatibility, gastrointestinal tract stimulation and the first-pass effect of the liver are avoided through transdermal drug delivery, and the safety is high; the medicine is standardized in preparation, simple and convenient to operate, suitable for primary medicine and families, capable of treating various diseases such as painful diseases and soft tissue injury and high in clinical application value.

The invention belongs to the technical field of microneedle patches, and discloses a sildenafil citrate microneedle patch preparation method, which comprises: 1, preparing a raw material solution; step 2, vacuum infusion; step 3, vacuum freeze-drying; step 4, demolding; step 5, detecting; and step 6, packaging. According to the sildenafil citrate microneedle patch, the bioavailability of the sildenafil citrate microneedle patch can be improved, the first-pass effect is effectively avoided, and a better way is provided for drug absorption and drug effect exertion; by developing a low-temperature drying process or a stabilizer formula, the drug degradation can be prevented. Meanwhile, the geometric structure of the microneedle is optimized, so that painless penetration can be ensured, deep tissues are not damaged, and the physical stability and the medicine effectiveness of the microneedle patch in the storage period can be ensured; the sildenafil citrate micro-needle patch takes effect quickly in a unique administration mode, and almost has no whole-body side effect; operation pain is avoided through the non-invasive characteristic, and the treatment comfort is improved.

The invention relates to a cabazitaxel self-emulsifying oral preparation and a preparation method thereof. The cabazitaxel self-emulsifying oral preparation is prepared from the following raw materials: a cabazitaxel active matter, grease, a surfactant and a cosurfactant, the cabazitaxel active matter is cabazitaxel or pharmaceutically acceptable salt, ester and solvate of cabazitaxel. After the cabazitaxel self-emulsifying oral preparation developed by the invention is in contact with an aqueous medium, nano-emulsion with small particle size (below 450 nm) can be spontaneously formed, drugs can be quickly released, and the first-pass effect of the liver can be bypassed through lymphatic transport, so that relatively high oral bioavailability is realized; the invention provides a comprehensive technical scheme capable of simultaneously solving the three problems of dissolution, permeation and metabolism, and a brand-new feasible path is opened up for oral administration of the cabazitaxel active matter.

Provided in the present invention are kemeiflufen hydrochloride and a crystal form thereof, a preparation method, and an application. The kemeiflufen hydrochloride of the present invention is 3-(3-ethyl-1-methyl-1H-hexahydroazepin-3-yl),2-(2-fluoro-4-biphenyl)-phenyl propionate hydrochloride, and has good solubility and stability, has a rapid medicinal effect, avoids the liver first-pass effect, improves bioavailability, and achieves the effects of reducing toxicity and enhancing efficacy. The preparation method for the kemeiflufen hydrochloride of the present invention is simple, and the product yield is high.

The invention discloses a microneedle patch with imrecoxib included by modified cyclodextrin as well as a preparation method and application of the microneedle patch, and relates to the technical field of biological medicines. The invention relates to a microneedle patch with imrecoxib included by modified cyclodextrin. The medicament of the microneedle patch is prepared from imrecoxib, crotamiton, carborane-beta-cyclodextrin and water. The carborane-beta-cyclodextrin clathrates imrecoxib and prepares the microneedle patch, so that the water solubility and transdermal efficiency of the fat-soluble drug imrecoxib can be remarkably improved, the first-pass effect and gastrointestinal reaction of oral administration can be avoided, and an efficient and safe local treatment scheme is provided for diseases such as knee osteoarthritis.

The invention discloses a salbutamol sulfate oral solution and a preparation method thereof.According to the salbutamol sulfate oral solution, a physical barrier is formed through inclusion of hydroxypropyl-beta-cyclodextrin, and a stability synergistic mechanism is formed through the chelating chemical inhibition effect of EDTA-2Na, so that the oxidative degradation rate of salbutamol sulfate is obviously reduced; in addition, sucralose and peppermint essence are used as flavoring agents for taste, high-sweetness taste modification and cool taste modification are performed, and triple taste masking of HP-beta-CD inclusion, sucralose and peppermint essence is performed, so that the taste score is remarkably improved; by destroying intestinal epithelium tight connection through sodium cholate, the transmembrane transport efficiency is improved, the bioavailability is improved, the apparent permeability coefficient (Papp) is remarkably improved, the problem of low availability caused by the first-pass effect is solved, beagle is orally taken, the bioavailability is remarkably improved, and the application prospect is remarkable.

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to a drug-loaded microsphere as well as a preparation method and application thereof. According to the invention, the bioadhesive material is used as a carrier and is mixed with the drug to form the drug-loaded microspheres with nasal mucosa adhesiveness, so that the residence time of the drug in the nasal cavity is prolonged, meanwhile, the stimulation of the drug to the nasal mucosa is reduced, the bioavailability and intracerebral distribution are improved, the administration dosage is reduced, the sustained release effect of the drug is realized, and adverse reactions of gastrointestinal tracts and the like are avoided. The drug-loaded microsphere provided by the invention has the following characteristics: because the nasal mucosa area is large, submucosa blood vessels are very rich, and the drug can be rapidly absorbed and enter systemic circulation from the blood vessels; the first-pass effect during oral administration of the medicine is avoided, and the bioavailability is relatively high; a unique direct channel exists between the nasal cavity and the brain in anatomy, and various macromolecular polypeptides and small molecular drugs can bypass a blood-brain barrier to enter cerebrospinal fluid or brain tissue after being absorbed by the nose.

The invention provides a microneedle administration method for treating gout, and relates to the field of gout administration, and the microneedle administration method comprises the following steps: S100, preparing a needle tip gel solution: mixing a gout treatment drug with hyaluronic acid, and stirring until the gout treatment drug and hyaluronic acid are completely dissolved to form a drug-loaded needle tip gel solution; s200, preparing a backing gel solution: dissolving hyaluronic acid in an aqueous solvent, and stirring until the hyaluronic acid is completely dissolved to form the backing gel solution. S300, injecting the needle tip gel solution into a needle hole of a microneedle mold, sequentially carrying out vacuum drying and centrifugal treatment to enable the needle hole to be fully filled with the solution, and drying the needle tip for 150 minutes; s400, the surface of a mold is covered with the backing gel solution, vacuum drying is conducted, and a backing layer is formed; and S500, demolding to obtain the drug-loaded microneedle patch, and attaching the drug-loaded microneedle patch to the skin of a patient to deliver a drug. The medicine is directly delivered to the corium layer through the microneedle, the liver first-pass effect and gastrointestinal tract degradation caused by oral administration are avoided, the medicine is released after microneedle puncture, and the medicine is suitable for rapid analgesia in the gout acute attack period, reduction of whole body exposure through local administration, reduction of the gastrointestinal ulcer occurrence rate of NSAIDs medicines and reduction of side effects. The length of the microneedle is 200-800 micrometers, the microneedle only penetrates through the cuticle, nerve endings are prevented from being damaged, the patch is packaged in a sterile aluminum-plastic bubble cap, a patient can attach the patch by himself / herself, and the requirement for frequently seeing a doctor is reduced.

Pharmaceutical compositions of the invention include substituted riluzole pro drugs useful for the treatment of amyotrophic lateral sclerosis (ALS) and related disorders through the release of riluzole, especially to avoid patient to patient variability in first pass, hepatic metabolism promoted by Cyp 1Λ2. Pro-drugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release rihizole in the plasma via either an enzymatic or general biophysical release process. The invention further includes pro-drugs of riluzole useful for the treatment of disease states that can be treated with riluzole through the release of rihizole from a pro-drug agent.

The invention relates to the technical field of pharmaceutical preparation science and technology, and discloses polygonum cuspidatum compound nano-cream as well as a preparation method and application thereof. The polygonum cuspidatum compound nano emulsifiable paste can synergistically exert the antibacterial, anti-inflammatory and anti-oxidation effects of PD, RV and SK, regulate and control key paths for acne attack in a targeted manner, improve the skin permeability of insoluble components and the retention volume of focus parts by virtue of the delivery advantage of glycyrrhizic acid nano-micelles, reduce the external irritation, and improve the curative effect of acne. The first-pass effect and the whole body toxic and side effects of oral administration are avoided, so that a novel preparation scheme with innovativeness and practicability is provided for safe and efficient treatment of acne.

The invention discloses a Mongolian medicine composition for treating chronic kidney diseases and application of the Mongolian medicine composition, and belongs to the technical field of biological medicine. The Mongolian medicine composition is prepared from the following components in parts by weight: 35 to 45 parts of radix et rhizoma rhei, 30 to 40 parts of halite, 15 to 25 parts of rhizoma kaempferiae, 20 to 30 parts of pomegranate, 15 to 25 parts of semen cassiae torae, 20 to 30 parts of rhizoma kaempferiae, 10 to 20 parts of radix inulae and 15 to 25 parts of fructus chebulae. According to the Mongolian medicine three-root seven-element theory, the viscera theory, the turbid metabolism theory and the holistic view, the Mongolian medicine composition with the remarkable curative effect on the chronic kidney disease is developed by combining the intestinal renal axis theory. According to the invention, enema administration is adopted, so that the medicine directly acts on intestinal mucosa, the first-pass effect of liver is avoided, and the utilization rate of the medicine is improved; the drug administration scheme is optimized, the operation is simple and convenient, and the safety is high. And the composition is completely prepared from natural Mongolian medicine components, so that the toxic and side effects are small, the patient compliance is better, and a new treatment thought is provided for clinical treatment of the chronic kidney disease.

The invention discloses a rifapentine capsule type dry powder inhaler and a preparation method thereof, the capsule type dry powder inhaler comprises a capsule shell and a capsule content, and the capsule content comprises the following components in parts by weight: 1 part of rifapentine, 1-30 parts of a carrier and 0.01-1 part of a flow aid. According to the invention, micronized drug bulk drugs and appropriate excipients are in the form of capsules, and atomized drugs are actively inhaled into the lungs by a patient through a specially-made dry powder inhalation device. The delivery efficiency of the preparation is high, and the lung deposition rate is high; the particle size of the preparation and the stability of the preparation are high, and the compatibility between raw materials and auxiliary materials is good. The rifapentine capsule type dry powder inhaler disclosed by the invention has no gastrointestinal tract degradation effect and no liver first-pass effect, the medicine can directly act on the lung, the absorption is quick, and the effect is quick after administration; meanwhile, local administration is realized, the dosage is obviously reduced, and toxic and side effects are small. The preparation method disclosed by the invention is simple and easy to implement, has no too high requirements on technical equipment, and is suitable for domestic industrial production.

The invention provides a film agent for treating migraine, the film agent at least comprises sumatriptan and pharmaceutically acceptable salts thereof, a film-forming material, a stabilizing agent, and one or more of a plasticizer and a sweetening agent, and the stabilizing agent is silicon dioxide. The silicon dioxide is added as a stabilizer when the film agent of sumatriptan and the salt thereof is prepared, so that the sumatriptan and the salt thereof can keep amorphous stability, crystals cannot be separated out, the stability of the curative effect is ensured, and the storage is facilitated. The film agent disclosed by the invention can be directly absorbed by oral mucosa to avoid the first-pass effect, the medicine is in an amorphous state in the film agent, the dissolution rate and bioavailability are improved, the release and absorption speed is higher, the medicine effect can be accelerated, and migraine can be relieved as soon as possible.

The invention provides comeflufen hydrochloride as well as a crystal form, a preparation method and application thereof. The comeflufen hydrochloride disclosed by the invention is 3-(3-ethyl-1-methyl-1H-hexahydroazepine-3-yl) and 2-(2-fluoro-4-biphenyl)-phenyl propionate hydrochloride, has good solubility and stability, is quick in drug effect, and can avoid the first-pass effect of the liver, improve the bioavailability and achieve the effects of reducing toxicity and enhancing efficiency; the preparation method of the comeflufen hydrochloride is simple, and the product yield is high.

The application discloses a Mongolian medicine composition for treating chronic kidney disease and application thereof, and belongs to the technical field of biological medicine. The Mongolian medicine composition comprises the following components: 35-45 parts of rhubarb, 30-40 parts of Guangming salt, 15-25 parts of alkali flower, 20-30 parts of Punica granatum, 15-25 parts of Cyclocarya paliurus, 20-30 parts of Kaempferia, 10-20 parts of Inula helenium and 15-25 parts of Terminalia chebula. According to the theory of three roots and seven elements, the theory of viscera, the theory of metabolism of clear and turbid and the whole view, and in combination with the theory of "gut-kidney axis", the Mongolian medicine composition with remarkable curative effect on chronic kidney disease is developed. The enema administration is adopted, the drug directly acts on the intestinal mucosa, the liver first-pass effect is avoided, the drug utilization rate is improved, the administration scheme is optimized, the operation is simple and the safety is high. Moreover, all the components of the composition are natural Mongolian medicine components, the toxic and side effects are small, the patient compliance is good, a new treatment idea is provided for the clinical treatment of chronic kidney disease.

This invention discloses a sustained-release transdermal patch containing magnolia oleoresin, its preparation method, and its application, belonging to the field of traditional Chinese medicine external preparation technology. The patch consists of a gel layer containing magnolia oleoresin extract, a backing layer, and a protective film. Sodium polyacrylate, PVP K90, glycerin, and chitosan quaternary ammonium salt are used as the gel matrix, with the addition of high-purity magnolia oleoresin extract and a penetration enhancer. The preparation method includes ethanol extraction and macroporous resin purification of magnolia oleoresin from magnolia oleoresin, preparation of a blank matrix, preparation of the drug solution, drug loading and mixing, coating and molding, and drying and cutting. The process is stable and controllable. The transdermal patch prepared by this invention can achieve sustained transdermal drug release, bypassing the first-pass effect of the liver. It is convenient to use, has high compliance, and provides a safe and effective new formulation for the treatment of rhinitis.

The invention belongs to the technical field of pharmaceutical preparations, and discloses a nasal vinpocetine salt gel as well as a preparation method and application thereof. The vinpocetine salt type derivative in the nasal vinpocetine salt gel precursor composition provided by the invention is used as a key functional component, relatively high bioavailability and brain entry efficiency are shown, the central Abeta removal efficiency is enhanced, a nasal gel drug delivery system is formed by the chitosan / carboxymethyl cellulose and the derivative thereof, and the drug delivery effect is improved. The double functions of prolonging retention and efficiently entering the brain are achieved, and the problem that the first-pass effect of vinpocetine medicine is remarkable is solved through the system.